Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 269

Results For "STI"

7031 News Found

Strides receives USFDA approval for anti-inflammatory Celecoxib Capsules
Drug Approval | May 01, 2025

Strides receives USFDA approval for anti-inflammatory Celecoxib Capsules

Celecoxib Capsules approval complements Strides’ existing products to serve a broader patient base


USFDA inspects Marksans’s subsidiary Time-Cap Laboratories' manufacturing facility
Drug Approval | May 01, 2025

USFDA inspects Marksans’s subsidiary Time-Cap Laboratories' manufacturing facility

The Subsidiary has received one inspectional observation in Form 483


Dr. Morepen launches Rs. 499 annual multivitamin pack on Labour’s Day
Healthcare | May 01, 2025

Dr. Morepen launches Rs. 499 annual multivitamin pack on Labour’s Day

Priced at just Rs. 499 for 1-year supply, this initiative is aligned with the vision of Health for All


Aster DM Healthcare completes acquisition of 5% stake in Quality Care India
News | May 01, 2025

Aster DM Healthcare completes acquisition of 5% stake in Quality Care India

The transaction structured as share swap, is valued at ~Rs. 849 crore, with no cash outflow


ekincare raises investment from MSD IDEA Studio Asia Pacific
News | April 30, 2025

ekincare raises investment from MSD IDEA Studio Asia Pacific

ekincare has raised a total funding of $22M since 2015 till date


Vimta Labs to invest Rs. 50 crores to Biologics CDMO business foray
News | April 29, 2025

Vimta Labs to invest Rs. 50 crores to Biologics CDMO business foray

The foray into this new segment will help Vimta to enter into the growing CDMO business of biologics and peptides


Thermo Fisher Scientific to invest $2 billion to expand US operation
News | April 29, 2025

Thermo Fisher Scientific to invest $2 billion to expand US operation

Investment demonstrates confidence in America’s commitment to science and innovation


Merck breaks ground on new $1 billion Biologics Center of Excellence in Delaware, US
News | April 29, 2025

Merck breaks ground on new $1 billion Biologics Center of Excellence in Delaware, US

Merck Wilmington Biotech will serve as a launch and commercial production facility and the future U.S. home for KEYTRUDA


Merck to acquire US Biopharma firm SpringWorks Therapeutics for enterprise value of $3.4 billion
Biopharma | April 28, 2025

Merck to acquire US Biopharma firm SpringWorks Therapeutics for enterprise value of $3.4 billion

Planned acquisition will strengthen the presence of Merck Healthcare in the United States and expand reach of SpringWorks’ therapeutic innovations to more patients with rare tumors worldwide